Correlation Between Acrivon Therapeutics, and Statera Biopharma

Can any of the company-specific risk be diversified away by investing in both Acrivon Therapeutics, and Statera Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Acrivon Therapeutics, and Statera Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Acrivon Therapeutics, Common and Statera Biopharma, you can compare the effects of market volatilities on Acrivon Therapeutics, and Statera Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Acrivon Therapeutics, with a short position of Statera Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Acrivon Therapeutics, and Statera Biopharma.

Diversification Opportunities for Acrivon Therapeutics, and Statera Biopharma

0.35

Correlation Coefficient

Acrivon Therapeutics,  Statera Biopharma

Weak diversification

The 3 months correlation between Acrivon and Statera is 0.35. Overlapping area represents the amount of risk that can be diversified away by holding Acrivon Therapeutics, Common and Statera Biopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Statera Biopharma and Acrivon Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Acrivon Therapeutics, Common are associated (or correlated) with Statera Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Statera Biopharma has no effect on the direction of Acrivon Therapeutics, i.e., Acrivon Therapeutics, and Statera Biopharma go up and down completely randomly.

Pair Corralation between Acrivon Therapeutics, and Statera Biopharma

If you would invest  3.61  in Statera Biopharma on September 15, 2024 and sell it today you would earn a total of  0.00  from holding Statera Biopharma or generate 0.0% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	1.56%
Values	Daily Returns

Acrivon Therapeutics, Common  vs.  Statera Biopharma

Acrivon Therapeutics,

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Acrivon Therapeutics, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unsteady performance, the Stock's basic indicators remain stable and the latest fuss on Wall Street may also be a sign of long-term gains for the venture sophisticated investors.

Statera Biopharma

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Statera Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, Statera Biopharma is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Pair Trading with Acrivon Therapeutics, and Statera Biopharma

The main advantage of trading using opposite Acrivon Therapeutics, and Statera Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Acrivon Therapeutics, position performs unexpectedly, Statera Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Statera Biopharma will offset losses from the drop in Statera Biopharma's long position.

The idea behind Acrivon Therapeutics, Common and Statera Biopharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.